Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,501.65 -12.72 -0.08%
S&P 500 1,875.39 -4.16 -0.22%
NASDAQ 4,126.97 -34.49 -0.83%
Ticker Volume Price Price Delta
STOXX 50 3,175.97 -23.72 -0.74%
FTSE 100 6,674.74 -7.02 -0.11%
DAX 9,544.19 -55.90 -0.58%
Ticker Volume Price Price Delta
NIKKEI 14,522.82 -23.45 -0.16%
TOPIX 1,171.47 -2.34 -0.20%
HANG SENG 22,509.64 -221.04 -0.97%

Cerus to Release First Quarter 2013 Results on April 30, 2013



  Cerus to Release First Quarter 2013 Results on April 30, 2013

Business Wire

CONCORD, Calif. -- April 17, 2013

Cerus Corporation (NASDAQ:CERS) announced today that its first quarter results
will be released on Tuesday, April 30, 2013, after the close of the stock
market. The company will host a conference call and webcast at 4:15 PM ET that
afternoon, during which management will discuss the Company’s financial
results and provide a general business overview and outlook.

To access the live webcast, please visit the Investor Relations page of the
Cerus website at http://www.cerus.com/ir. Alternatively, you may access the
live conference call by dialing 866-235-9006 (U.S.) or 631-291-4549
(international).

A replay will be available on the company’s website, or by dialing
855-859-2056 (U.S.) or 404-537-3406 (international) and entering conference ID
number 31976328. The replay will be available approximately three hours after
the call through May 13, 2013.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused on commercializing
the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is
designed to reduce the risk of transfusion-transmitted diseases by
inactivating a broad range of pathogens such as viruses, bacteria and
parasites that may be present in donated blood. The nucleic acid targeting
mechanism of action enables INTERCEPT treatment to inactivate established
transfusion threats, such as hepatitis B and C, HIV, West Nile virus and
bacteria, and is designed to inactivate emerging pathogens such as influenza,
malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood
System for both platelets and plasma in Europe, the Commonwealth of
Independent States, the Middle East and selected countries in other regions
around the world. In the United States, Cerus is seeking regulatory approval
of the INTERCEPT Blood System for plasma, and is in discussion with FDA to
define the additional clinical data required for a regulatory submission for
the INTERCEPT Blood System for platelets. The INTERCEPT Blood System for red
blood cells is in clinical development. See http://www.cerus.com for more
information.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Contact:

Cerus Corporation
Kevin D. Green, 925-288-6138
Vice President, Finance & CAO
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement